Total Payments
$60,100
2024 Payments
$6,159
Companies
16
Transactions
68
Medicare Patients
622
Medicare Billing
$117,364
Payment Breakdown by Category
Consulting$31,067 (51.7%)
Other$17,672 (29.4%)
Research$7,800 (13.0%)
Travel$2,437 (4.1%)
Food & Beverage$1,125 (1.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $31,067 | 17 | 51.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $14,172 | 17 | 23.6% |
| Unspecified | $7,800 | 3 | 13.0% |
| Honoraria | $2,500 | 1 | 4.2% |
| Travel and Lodging | $2,437 | 8 | 4.1% |
| Food and Beverage | $1,125 | 19 | 1.9% |
| Charitable Contribution | $500.00 | 1 | 0.8% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $500.00 | 2 | 0.8% |
Payments by Type
General
$52,300
65 transactions
Research
$7,800
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $15,515 | 15 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $10,271 | 13 | $0 (2024) |
| Merck Sharp & Dohme LLC | $7,848 | 9 | $0 (2022) |
| Amgen Inc. | $6,339 | 4 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $5,358 | 7 | $0 (2020) |
| ARRAY BIOPHARMA INC | $3,945 | 4 | $0 (2023) |
| Exelixis Inc. | $3,000 | 2 | $0 (2021) |
| Shionogi Inc | $2,212 | 3 | $0 (2020) |
| Incyte Corporation | $2,207 | 2 | $0 (2018) |
| Partner Therapeutics, Inc. | $1,600 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,159 | 3 | Regeneron Pharmaceuticals, Inc. ($4,284) |
| 2023 | $7,370 | 13 | Regeneron Pharmaceuticals, Inc. ($5,899) |
| 2022 | $11,228 | 12 | Merck Sharp & Dohme LLC ($7,848) |
| 2021 | $5,400 | 3 | ARRAY BIOPHARMA INC ($2,500) |
| 2020 | $6,960 | 3 | PFIZER INC. ($3,200) |
| 2019 | $8,500 | 12 | E.R. Squibb & Sons, L.L.C. ($1,725) |
| 2018 | $5,755 | 12 | PFIZER INC. ($2,220) |
| 2017 | $8,728 | 10 | Amgen Inc. ($5,585) |
All Payment Transactions
68 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/19/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $3,295.00 | General |
| Category: ONCOLOGY | ||||||
| 09/19/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $988.50 | General |
| Category: ONCOLOGY | ||||||
| 01/03/2024 | PFIZER INC. | BRAFTOVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,875.00 | General |
| Category: ONCOLOGY | ||||||
| 06/06/2023 | ARRAY BIOPHARMA INC | MEKTOVI (Drug), BRAFTOVI | Food and Beverage | In-kind items and services | $102.95 | General |
| Category: ONCOLOGY | ||||||
| 04/06/2023 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,416.00 | General |
| 04/06/2023 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,208.00 | General |
| 04/06/2023 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $604.00 | General |
| 04/06/2023 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $604.00 | General |
| 04/06/2023 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $604.00 | General |
| 04/06/2023 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $302.00 | General |
| 02/06/2023 | BioNTech SE | — | Food and Beverage | In-kind items and services | $117.76 | General |
| 01/27/2023 | Regeneron Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $48.86 | General |
| 01/27/2023 | Regeneron Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $47.36 | General |
| 01/27/2023 | Regeneron Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $40.59 | General |
| 01/27/2023 | Regeneron Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $24.36 | General |
| 01/03/2023 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,250.00 | General |
| Category: ONCOLOGY | ||||||
| 09/11/2022 | Regeneron Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $88.70 | General |
| 06/29/2022 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $6,710.00 | General |
| 06/29/2022 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 06/23/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $310.00 | General |
| Category: ONCOLOGY | ||||||
| 06/23/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $163.75 | General |
| Category: ONCOLOGY | ||||||
| 06/23/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $64.28 | General |
| Category: ONCOLOGY | ||||||
| 06/23/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $54.91 | General |
| Category: ONCOLOGY | ||||||
| 06/23/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $51.46 | General |
| Category: ONCOLOGY | ||||||
| 06/22/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $196.66 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ONCOLOGY PORTFOLIO CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $4,600 | 2 |
| NIROGACESTAT CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 156 | 265 | $132,626 | $29,291 |
| 2022 | 4 | 174 | 343 | $145,090 | $35,716 |
| 2021 | 3 | 118 | 252 | $96,566 | $25,160 |
| 2020 | 4 | 174 | 300 | $125,382 | $27,198 |
Total Patients
622
Total Services
1,160
Medicare Billing
$117,364
Procedure Codes
14
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 94 | 179 | $95,272 | $19,211 | 20.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 43 | 43 | $25,085 | $5,944 | 23.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 19 | 43 | $12,269 | $4,136 | 33.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 98 | 178 | $91,506 | $20,473 | 22.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 36 | 125 | $35,375 | $10,337 | 29.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 26 | 26 | $13,898 | $3,774 | 27.2% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 14 | 14 | $4,311 | $1,132 | 26.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 77 | 119 | $58,785 | $13,863 | 23.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 30 | 120 | $33,960 | $10,163 | 29.9% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 11 | 13 | $3,821 | $1,135 | 29.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 90 | 164 | $78,377 | $14,501 | 18.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 22 | 71 | $20,093 | $6,125 | 30.5% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 37 | 37 | $20,370 | $4,919 | 24.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 25 | 28 | $6,542 | $1,652 | 25.2% |
About Dr. Adi Diab, M.D
Dr. Adi Diab, M.D is a Medical Oncology healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/16/2008. The National Provider Identifier (NPI) number assigned to this provider is 1063676245.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Adi Diab, M.D has received a total of $60,100 in payments from pharmaceutical and medical device companies, with $6,159 received in 2024. These payments were reported across 68 transactions from 16 companies. The most common payment nature is "Consulting Fee" ($31,067).
As a Medicare-enrolled provider, Diab has provided services to 622 Medicare beneficiaries, totaling 1,160 services with total Medicare billing of $117,364. Data is available for 4 years (2020–2023), covering 14 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Houston, TX
- Active Since 07/16/2008
- Last Updated 04/19/2024
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1063676245
Products in Payments
- BRAFTOVI (Drug) $5,625
- Parsabiv (Biological) $5,037
- LIBTAYO (Biological) $4,284
- OPDIVO (Biological) $3,075
- Leukine (Drug) $1,600
- CABOMETYX (Drug) $1,500
- DSP-0509 (Drug) $1,000
- KEYTRUDA (Biological) $987.91
- MEKTOVI (Drug) $194.82
- MEKINIST (Drug) $85.62
- TAFINLAR (Drug) $50.08
- Fycompa (Drug) $15.87
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Houston
Roy Herbst, M.d., Phd, M.D., PHD
Medical Oncology — Payments: $1.6M
Medical Oncology $1.6M
Dr. Putao Cen, Md, MD
Medical Oncology — Payments: $817,580
Medical Oncology $817,580
Hagop Kantarjian, Md, MD
Medical Oncology — Payments: $740,835
Medical Oncology $740,835
Dr. Matthew Ellis, Md Phd, MD PHD
Medical Oncology — Payments: $714,994
Medical Oncology $714,994
Eleni Efstathiou, M.d, M.D
Medical Oncology — Payments: $600,908
Medical Oncology $600,908
Srdan Verstovsek, M.d., Phd, M.D., PHD
Medical Oncology — Payments: $577,763
Medical Oncology $577,763